Living Cell Technologies
Living Cell Technologies | Home.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Grant | ||
| Total Funding | 000k | ||
| AUD | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (99304 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (30570 %) | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 75246 % | - | - | - |
Source: Company filings or news article
Related Content
LCT Global is a biotechnology company focused on discovering, developing, and commercializing regenerative treatments for serious diseases. The company specializes in using naturally occurring cells, such as neonatal porcine choroid plexus cells, encapsulated in alginate to restore function in affected patients. LCT Global operates in the healthcare and biotechnology markets, targeting both clinical and commercial applications. The business model revolves around research and development, clinical trials, and partnerships with other healthcare organizations to bring their innovative therapies to market. Revenue is generated through licensing agreements, partnerships, and eventual sales of approved treatments.
Keywords: regenerative treatments, biotechnology, neonatal porcine cells, alginate capsules, healthcare, clinical trials, partnerships, licensing, commercialization, innovative therapies.